# Bipolar Androgen Therapy + Carboplatin in mCRPC

> **NCT03522064** · PHASE2 · RECRUITING · sponsor: **St Vincent's Hospital, Sydney** · enrollment: 30 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** Testosterone Enanthate 100 MG/ML Injectable Solution
- **DRUG:** Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5

## Key facts

- **NCT ID:** NCT03522064
- **Lead sponsor:** St Vincent's Hospital, Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-07-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522064, "Bipolar Androgen Therapy + Carboplatin in mCRPC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03522064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*